NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Biotech Hunter

Enrollment

515

Participants

Timeline

Start Date

December 17, 2012

Primary Completion Date

March 1, 2019

Study Completion Date

August 13, 2020

Conditions

Gastric AdenocarcinomaEsophageal CancerHepatocellular CarcinomaNon-small Cell Lung CancerSmall Cell Lung CancerOvarian Epithelial CancerCarcinoma Breast Stage IVHormone-refractory Prostate CancerHead and Neck Cancers- Squamous CellRenal Cell CancerUrinary Bladder NeoplasmsCervical CancerEndometrial CancerGlioblastoma MultiformeTriple Negative Breast CancerPancreatic Cancer

Interventions

DRUG

Sacituzumab Govitecan-hziy (SG)

Administered via intravenous (IV) infusion

Trial Locations (12)

10021

Weill Cornell/New York Presbyterian Hospital, New York

10032

Columbia University Herbert Irving Cancer Center, New York

19713

Helen F. Graham Cancer Center, Newark

32806

MD Anderson Cancer Center Orlando (UF Health Cancer Center), Orlando

33612

Moffitt Cancer Center, Tampa

37212

Vanderbilt-Ingram Cancer Center, Nashville

46526

IU Health Goshen Cancer Center, Goshen

75246

Texas Oncology Sammons Cancer Center, Dallas

98111

Virginia Mason Cancer Center, Seattle

080045

University of Colorado Anschutz Medical Campus, Aurora

06511

Yale University School of Medicine, New Haven

02114

Massachusettes General Hospital, Boston